Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

ASCO 2024 Updates in the Treatment of Renal Cell Carcinoma and Evolving Data on Non-Clear Cell Renal Cell Carcinoma

Video Series

Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis

Martin H. Voss, MD, and Moshe C. Ornstein, MD, review significant renal cell carcinoma research developments presented at ASCO 2024, highlighting data and insights poised to reshape the disease's treatment landscape.

Key opinion leaders explore renal cell carcinoma subtypes, their incidence rates, primary sites of origin, and frequently observed genetic mutations.

Overview of RCC Histology and Incidence Rates

Key opinion leaders analyze recent findings from the CLEAR trial presented at ASCO 2024, focusing on the four-year follow-up data for progression-free survival and overall survival outcomes.

CLEAR Trial Updates From ASCO 2024

Key opinion leaders examine the application of tyrosine kinase inhibitors (TKIs) and evaluate first-line therapeutic approaches for renal cell carcinoma. 

TKIs, Disease Progression and Subsequent Therapy in RCC 

Key opinion leaders analyze the latest advancements and research findings specific to Non-Clear Cell Renal Cell Carcinoma presented at the American Society of Clinical Oncology 2024 conference. 

ASCO 2024 Updates: nccRCC + Chromophobe RCC 

Key opinion leaders examine the Phase II PAPMET clinical trial, focusing on its design and progression-free survival outcomes. 

PAPMET Phase II Trial Advances Cancer Treatment Landscape 

Renal cell carcinoma specialists provide a comprehensive overview of chromophobe renal cell carcinoma (ChRCC), including its definition, background, and distinctive characteristics. 

Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis 

The expert panel explores predictors of chromophobe renal cell carcinoma recurrence and other critical factors that inform treatment decisions for patients. 

Examining Predictors of Chromophobe Renal Cell Carcinoma Recurrence 

Medical experts in renal cell carcinoma provide an overview of abstract 4512 presented at ASCO 2024.  

ASCO 2024: Abstract 4512 Overview 

The panel examines the key findings from abstract 4512 and evaluates its potential impact on the current treatment paradigm for renal cell carcinoma. 

Key Takeaways in Renal Cell Carcinoma from Abstract 4512 

Medical experts compare the updated results of a Phase II trial and KEYNOTE B-61, both presented at ASCO 2024, giving a comprehensive overview of these pivotal studies. 

Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials 

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis

EP: 1.Overview of RCC Histology and Incidence Rates

EP: 2.CLEAR Trial Updates From ASCO 2024

EP: 3.TKIs, Disease Progression and Subsequent Therapy in RCC

EP: 4.ASCO 2024 Updates: nccRCC + Chromophobe RCC

EP: 5.PAPMET Phase II Trial Advances Cancer Treatment Landscape

EP: 6.Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis

EP: 7.Examining Predictors of Chromophobe Renal Cell Carcinoma Recurrence

EP: 8.ASCO 2024: Abstract 4512 Overview

EP: 9.Key Takeaways in Renal Cell Carcinoma from Abstract 4512

EP: 10.Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials